Andréa Varga

Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

Antoîne Italiano, Jean‐Charles Soria, Maud Toulmonde et al. · The Lancet Oncology · 2018 · 614 citations

Medicine, Oncology, Pharmacology +12

Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1–Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial

Jean‐Sébastien Frenel, Christophe Le Tourneau, Bert H. O’Neil et al. · Journal of Clinical Oncology · 2017 · 534 citations

Pharmacy, Oncology, Pharmacotherapy +14

Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the <scp>KEYNOTE</scp>‐158 and <scp>KEYNOTE</scp>‐028 studies

Sarina A. Piha‐Paul, Do‐Youn Oh, Makoto Ueno et al. · International Journal of Cancer · 2020 · 498 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +15

Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Hope S. Rugo, Jean‐Pierre Delord, Seock‐Ah Im et al. · Clinical Cancer Research · 2018 · 387 citations

Medicine, Oncology, Pharmacology +17

Evaluation of Readministration of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer

Audrey Simonaggio, Jean‐Marie Michot, Anne Laure Voisin et al. · JAMA Oncology · 2019 · 372 citations · Full text

Medicine, Oncology, Pharmacology +17